Samsara BioCapital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Samsara BioCapital’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,285	Closed	-$3.06M	–	25
2025 Q3	$3.06M	Sell	30,285 -20,191	-40%	-$1.87M	0.4%	22
2025 Q2	$3.19M	Sell	50,476 -87,642	-63%	-$5.37M	0.65%	18
2025 Q1	$7.32M	Sell	138,118 -34,529	-20%	-$1.92M	1.3%	14
2024 Q4	$9.66M	Hold	172,647	–	–	1.33%	13
2024 Q3	$9.04M	Hold	172,647	–	–	1.74%	16
2024 Q2	$7.09M	Hold	172,647	–	–	1.48%	17
2024 Q1	$7.48M	Hold	172,647	–	–	1.16%	18
2023 Q4	$7.94M	Sell	172,647 -172,646	-50%	-$5.45M	1.23%	16
2023 Q3	$7.92M	Hold	345,293	–	–	2.42%	12
2023 Q2	$5.69M	Hold	345,293	–	–	1%	20
2023 Q1	$6.16M	Hold	345,293	–	–	1.27%	17
2022 Q4	$10.1M	Hold	345,293	–	–	2.16%	13
2022 Q3	$8.46M	Hold	345,293	–	–	1.97%	15
2022 Q2	$1.43M	Hold	345,293	–	–	0.38%	39
2022 Q1	$3.98M	Hold	345,293	–	–	1%	27
2021 Q4	$3.45M	Buy	345,293 +45,000	+15%	+$506K	0.67%	29
2021 Q3	$3.92M	Hold	300,293	–	–	0.62%	32
2021 Q2	$5.88M	Buy	300,293 +99,247	+49%	+$2.06M	0.73%	26
2021 Q1	$4.28M	Hold	201,046	–	–	0.79%	29
2020 Q4	$5.98K	Sell	201,046 -33,800	-14%	-$859K	0.6%	18
2020 Q3	$5.09M	Sell	234,846 -41,443	-15%	-$950K	1.42%	18
2020 Q2	$6.16M	Hold	276,289	–	–	1.98%	14
2020 Q1	$4.21M	Buy	+276,289	New	+$4.95M	2.42%	11

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Samsara BioCapital's RYTM Position: Q4 2025 in Review

Samsara BioCapital sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 30,285 shares — an estimated $3.06M sold.

Samsara BioCapital first reported a position in RYTM in Q1 2020 and held it in 23 quarters. The position peaked at $10.1M in Q4 2022. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

Samsara BioCapital reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Samsara BioCapital sold 30,285 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $3.06M.
Samsara BioCapital first reported a position in Rhythm Pharmaceuticals in Q1 2020 and held it in 23 quarters.
Samsara BioCapital's Rhythm Pharmaceuticals position peaked at $10.1M in Q4 2022.
279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.